In addition, use of another ERK5 inhibitor, XMD8‐92, resulted in reductions of the phagocytic ability of alveolar macrophages in the LPS + UTI + BIX02189 group (Fig. 5D,I) and lung histopathology scores (Fig. 5E,J). This evidence concerns the gene MAPK7 and bacterial urinary tract infection.